On January 16 the Scottish Medicines Consortium (SMC) published advice accepting Zepatier for routine use in NHS Scotland.

Elbasvir-grazoprevir (Zepatier) was accepted for the treatment of chronic hepatitis C. Elbasvir-grazoprevir is a combination of two medicines that inhibit the replication of the hepatitis C virus and offers the prospect of a cure for hepatitis C infection.

“Eradicating hepatitis C is a key commitment for Scottish Government and new medicines for this condition will help achieve this aim.” (Professor Jonathan Fox, chairman of the SMC)

Source

Related News

1371

Behavioral intervention reduces HIV transmission risk in young transgender women

1717

Global progress towards hepatitis C elimination still blocked by cost of treatment, lack of diagnosis

1702

Vladimir Zhovtyak: European AIDS conference is a step forward to control the HIV/AIDS in Europe

1613

Patient Communities Agree on Shared Vision of HIV Treatment Regimen

2069

Glecaprevir/pibrentasvir is effective for people with HIV/HCV co-infection